I must premise that the GOLD strategy includes recommendations and should not be interpreted as a guideline. Surely we must feel indebted to those who have, over time, developed the GOLD Strategy, but we must also be aware that there are points that are not the unanimous opinion of all experts and clinicians involved in the management of patients with chronic obstructive pulmonary disease (COPD).
The latest definition of COPD is 'a common, preventable and treatable disease that is characterised by persistent respiratory symptoms and airflow limitation that is due to airway and/or alveolar abnormalities usually caused by significant exposure to noxious particles or gases. we must always adjust therapy taking into account the comorbidities that in a patient with COPD are very frequent.
However, it seems fair to me to point out that in the GOLD document, all of these aspects are discussed, but many physicians often focus only on definition and this can be misleading.
Q: What changes have been made to the airway, breathing, circulation, disability, exposure assessment tool?
Although spirometry in conjunction with patient symptoms and exacerbation history, remains vital for the diagnosis, prognostication and consideration of other important therapeutic approaches, a refinement of the airway, breathing, circulation, disability, exposure (ABCDE) assessment tool has been suggested, which separates spirometric grades from the ABCDE groups. For some therapeutic recommendations, ABCDE groups will be derived exclusively from patient symptoms and their history of exacerbation. This is not a real surprise because we cannot forget that in the UNLOCK study, 12% of GOLD I (mild COPD) European patients in primary care were frequent exacerbators (two or more acute exacerbations of COPD [AECOPD] yearly), and 34% exacerbated at least once yearly. 2 Furthermore, evidence proves that patients can shift from one category (frequent exacerbator or infrequent exacerbator) to another, but there is no clear explanation or marker for this shift, apart from the fact that patients on the borderline between infrequent and frequent AECOPDs are more likely to change category and this trend is regardless of the value of spirometry. that it is always better to avoid a therapeutic step-up progression when it is not needed rather than being forced subsequently into a step-down approach in which the outcome is always unpredictable.
All these considerations are absent in the 2017 GOLD report and this lack makes it impossible to establish with good approximation the value of escalation and de-escalation of therapy in COPD.
